{"id": "article-25891_0", "title": "Nimodipine -- Continuing Education Activity", "content": "Nimodipine is a second-generation 1,4-dihydropyridine calcium channel blocker that\u00a0was originally approved by the FDA to manage hypertension. Today, nimodipine is predominantly used to manage vasospasm subsequent to subarachnoid hemorrhage, in addition to off-label applications.\u00a0Nimodipine is available\u00a0in various formulations, including oral tablets, solutions, and intravenous infusions. This discussion will primarily focus on\u00a0this medication's administration methods and associated considerations. Equally important are the indications, mechanisms of action, adverse effects, contraindications, and monitoring associated with nimodipine administration. Healthcare professionals must have a deep comprehension of this medication in order to use it effectively. This\u00a0informed decision-making not only optimizes dosage regimens but also mitigates adverse reactions, facilitating enhanced patient outcomes in subarachnoid hemorrhage scenarios treated with nimodipine.", "contents": "Nimodipine -- Continuing Education Activity. Nimodipine is a second-generation 1,4-dihydropyridine calcium channel blocker that\u00a0was originally approved by the FDA to manage hypertension. Today, nimodipine is predominantly used to manage vasospasm subsequent to subarachnoid hemorrhage, in addition to off-label applications.\u00a0Nimodipine is available\u00a0in various formulations, including oral tablets, solutions, and intravenous infusions. This discussion will primarily focus on\u00a0this medication's administration methods and associated considerations. Equally important are the indications, mechanisms of action, adverse effects, contraindications, and monitoring associated with nimodipine administration. Healthcare professionals must have a deep comprehension of this medication in order to use it effectively. This\u00a0informed decision-making not only optimizes dosage regimens but also mitigates adverse reactions, facilitating enhanced patient outcomes in subarachnoid hemorrhage scenarios treated with nimodipine."}
{"id": "article-25891_1", "title": "Nimodipine -- Continuing Education Activity", "content": "Objectives: Identify the mechanism of action of nimodipine. Differentiate between\u00a0the FDA-approved indications and the off-label indications of\u00a0nimodipine. Identify\u00a0the contraindications of nimodipine. Implement effective collaboration and communication among interprofessional team members to improve outcomes and treatment efficacy for patients who might benefit from\u00a0nimodipine\u00a0treatment. Access free multiple choice questions on this topic.", "contents": "Nimodipine -- Continuing Education Activity. Objectives: Identify the mechanism of action of nimodipine. Differentiate between\u00a0the FDA-approved indications and the off-label indications of\u00a0nimodipine. Identify\u00a0the contraindications of nimodipine. Implement effective collaboration and communication among interprofessional team members to improve outcomes and treatment efficacy for patients who might benefit from\u00a0nimodipine\u00a0treatment. Access free multiple choice questions on this topic."}
{"id": "article-25891_2", "title": "Nimodipine -- Indications", "content": "Nimodipine (C 21 H 26 N 2 O 7 ) is a second-generation 1,4-dihydropyridine calcium channel blocker initially developed to manage systemic hypertension. The FDA approved its use\u00a0in 1988. However, its current use is restricted\u00a0primarily\u00a0to managing vasospasm following subarachnoid hemorrhage.", "contents": "Nimodipine -- Indications. Nimodipine (C 21 H 26 N 2 O 7 ) is a second-generation 1,4-dihydropyridine calcium channel blocker initially developed to manage systemic hypertension. The FDA approved its use\u00a0in 1988. However, its current use is restricted\u00a0primarily\u00a0to managing vasospasm following subarachnoid hemorrhage."}
{"id": "article-25891_3", "title": "Nimodipine -- Indications -- FDA-Approved Indication", "content": "Prevention and treatment of cerebral vasospasm following subarachnoid hemorrhage. Nimodipine is indicated to improve neurological outcomes by reducing the incidence and severity of ischemic deficits regardless of their post-ictus neurological condition. [1]", "contents": "Nimodipine -- Indications -- FDA-Approved Indication. Prevention and treatment of cerebral vasospasm following subarachnoid hemorrhage. Nimodipine is indicated to improve neurological outcomes by reducing the incidence and severity of ischemic deficits regardless of their post-ictus neurological condition. [1]"}
{"id": "article-25891_4", "title": "Nimodipine -- Indications -- Off-Label Uses", "content": "Diffuse brain injury along with hyperbaric oxygen therapy [2] Assisting recovery after cranial nerve injury [3] Migraine\u00a0prevention [4] Peripheral vertigo and M\u00e9ni\u00e8re disease [5] Reducing the development of postoperative delirium in\u00a0older patients under general anesthesia [6] Drug-resistant epilepsy [7] Orgasmic and bath-related headaches [8] [9] Potential for glaucoma\u00a0management as an ophthalmic formulation [10] The following findings are derived from various trials regarding the use of nimodipine:", "contents": "Nimodipine -- Indications -- Off-Label Uses. Diffuse brain injury along with hyperbaric oxygen therapy [2] Assisting recovery after cranial nerve injury [3] Migraine\u00a0prevention [4] Peripheral vertigo and M\u00e9ni\u00e8re disease [5] Reducing the development of postoperative delirium in\u00a0older patients under general anesthesia [6] Drug-resistant epilepsy [7] Orgasmic and bath-related headaches [8] [9] Potential for glaucoma\u00a0management as an ophthalmic formulation [10] The following findings are derived from various trials regarding the use of nimodipine:"}
{"id": "article-25891_5", "title": "Nimodipine -- Indications", "content": "One recent study\u00a0reports that a considerable risk of mortality and morbidity is associated with SAH; nearly half of survivors experience significant cognitive dysfunction that affects their functional status and quality of life. Besides the severity of the initial hemorrhage, secondary brain injury resulting from early brain injury and delayed cerebral ischemia significantly impacts\u00a0outcomes for\u00a0patients with SAH. Although numerous strategies to address secondary brain injury have been explored, only nimodipine has demonstrated effectiveness in improving long-term functional outcomes. [11]", "contents": "Nimodipine -- Indications. One recent study\u00a0reports that a considerable risk of mortality and morbidity is associated with SAH; nearly half of survivors experience significant cognitive dysfunction that affects their functional status and quality of life. Besides the severity of the initial hemorrhage, secondary brain injury resulting from early brain injury and delayed cerebral ischemia significantly impacts\u00a0outcomes for\u00a0patients with SAH. Although numerous strategies to address secondary brain injury have been explored, only nimodipine has demonstrated effectiveness in improving long-term functional outcomes. [11]"}
{"id": "article-25891_6", "title": "Nimodipine -- Indications", "content": "Current evidence suggests nimodipine may reduce the risk of death or vegetative state related to delayed cerebral ischemia (DCI). However, some studies also indicate that fixed-dose regimens may decrease mortality and infarction rates. Further research is needed to determine nimodipine's broader benefits and the optimal dosing strategy\u00a0for contemporary practice. [12]", "contents": "Nimodipine -- Indications. Current evidence suggests nimodipine may reduce the risk of death or vegetative state related to delayed cerebral ischemia (DCI). However, some studies also indicate that fixed-dose regimens may decrease mortality and infarction rates. Further research is needed to determine nimodipine's broader benefits and the optimal dosing strategy\u00a0for contemporary practice. [12]"}
{"id": "article-25891_7", "title": "Nimodipine -- Indications", "content": "Reducing\u00a0nimodipine doses must be performed cautiously in patients with high vasopressor demand after an aneurysmal subarachnoid hemorrhage (aSAH). One study examined risks during days 5 to 10 post-hemorrhage. Among 205 patients, 53% had reduced dosage ('reduction group'). This group had worse World Federation of Neurosurgical Societies (WFNS) and Fisher grades and more delayed cerebral ischemia (DCI), cerebral vasospasm (CVS), DCI-related infarction, and other unfavorable outcomes. Multivariable analysis identified 'reduced nimodipine dose' as the sole predictor for DCI and CVS. 'Poor WFNS grade' and 'reduced nimodipine dose' were linked to DCI-related infarction, while 'older age,' 'poor WFNS grade,' and 'reduced nimodipine dose' correlated with unfavorable outcomes at\u00a03\u00a0months. This study concludes that reducing nimodipine dosage during days 5 to 10 post-hemorrhage might negate its benefits and should be carefully considered. [13]", "contents": "Nimodipine -- Indications. Reducing\u00a0nimodipine doses must be performed cautiously in patients with high vasopressor demand after an aneurysmal subarachnoid hemorrhage (aSAH). One study examined risks during days 5 to 10 post-hemorrhage. Among 205 patients, 53% had reduced dosage ('reduction group'). This group had worse World Federation of Neurosurgical Societies (WFNS) and Fisher grades and more delayed cerebral ischemia (DCI), cerebral vasospasm (CVS), DCI-related infarction, and other unfavorable outcomes. Multivariable analysis identified 'reduced nimodipine dose' as the sole predictor for DCI and CVS. 'Poor WFNS grade' and 'reduced nimodipine dose' were linked to DCI-related infarction, while 'older age,' 'poor WFNS grade,' and 'reduced nimodipine dose' correlated with unfavorable outcomes at\u00a03\u00a0months. This study concludes that reducing nimodipine dosage during days 5 to 10 post-hemorrhage might negate its benefits and should be carefully considered. [13]"}
{"id": "article-25891_8", "title": "Nimodipine -- Indications", "content": "Nimodipine should be given to patients with no neurological deficits after subarachnoid hemorrhage to reduce the\u00a0risk of new neurological deficits due to vasospasm. [1]", "contents": "Nimodipine -- Indications. Nimodipine should be given to patients with no neurological deficits after subarachnoid hemorrhage to reduce the\u00a0risk of new neurological deficits due to vasospasm. [1]"}
{"id": "article-25891_9", "title": "Nimodipine -- Indications", "content": "Oral nimodipine 60 mg every 4 hours was well tolerated, reduced cerebral infarction, and improved outcomes after a subarachnoid hemorrhage. [14]", "contents": "Nimodipine -- Indications. Oral nimodipine 60 mg every 4 hours was well tolerated, reduced cerebral infarction, and improved outcomes after a subarachnoid hemorrhage. [14]"}
{"id": "article-25891_10", "title": "Nimodipine -- Indications", "content": "There is no statistically proven benefit of nimodipine in head injury patients. [15]", "contents": "Nimodipine -- Indications. There is no statistically proven benefit of nimodipine in head injury patients. [15]"}
{"id": "article-25891_11", "title": "Nimodipine -- Indications", "content": "Nimodipine has no role in improving the functional outcome of acute ischemic hemispheric stroke. [16]", "contents": "Nimodipine -- Indications. Nimodipine has no role in improving the functional outcome of acute ischemic hemispheric stroke. [16]"}
{"id": "article-25891_12", "title": "Nimodipine -- Indications", "content": "There is no benefit of nimodipine in the treatment of head injury patients. [17]", "contents": "Nimodipine -- Indications. There is no benefit of nimodipine in the treatment of head injury patients. [17]"}
{"id": "article-25891_13", "title": "Nimodipine -- Indications", "content": "Nimodipine has a minimal role in the\u00a0prevention of migraine without aura. [18]", "contents": "Nimodipine -- Indications. Nimodipine has a minimal role in the\u00a0prevention of migraine without aura. [18]"}
{"id": "article-25891_14", "title": "Nimodipine -- Indications", "content": "Researchers noted a beneficial effect\u00a0of nimodipine in acute cerebral ischemia. [19]", "contents": "Nimodipine -- Indications. Researchers noted a beneficial effect\u00a0of nimodipine in acute cerebral ischemia. [19]"}
{"id": "article-25891_15", "title": "Nimodipine -- Indications", "content": "Nimodipine may be effective in patients with small vessel subcortical vascular dementia. [20]", "contents": "Nimodipine -- Indications. Nimodipine may be effective in patients with small vessel subcortical vascular dementia. [20]"}
{"id": "article-25891_16", "title": "Nimodipine -- Indications", "content": "Early supplementation of nimodipine in stroke patients does\u00a0not have any beneficial effect. [21]", "contents": "Nimodipine -- Indications. Early supplementation of nimodipine in stroke patients does\u00a0not have any beneficial effect. [21]"}
{"id": "article-25891_17", "title": "Nimodipine -- Indications", "content": "Oral and intravenous nimodipine are equally efficient in preventing vasospasm following subarachnoid hemorrhage. [22]", "contents": "Nimodipine -- Indications. Oral and intravenous nimodipine are equally efficient in preventing vasospasm following subarachnoid hemorrhage. [22]"}
{"id": "article-25891_18", "title": "Nimodipine -- Indications", "content": "Nimodipine has a potential neuroprotective effect by preventing calcium overload in ischemic neurons. However, this is outweighed by its harmful hemodynamic effects in the ischemic area in treating acute ischemic stroke.", "contents": "Nimodipine -- Indications. Nimodipine has a potential neuroprotective effect by preventing calcium overload in ischemic neurons. However, this is outweighed by its harmful hemodynamic effects in the ischemic area in treating acute ischemic stroke."}
{"id": "article-25891_19", "title": "Nimodipine -- Indications", "content": "One Phase\u00a0III randomized trial compared the efficacy and safety\u00a0of\u00a0single intraventricular administration\u00a0nimodipine microparticles to the standard oral nimodipine\u00a0in patients with SAH.\u00a0The trial concluded that sustained release nimodipine administered via external ventricular drain did not\u00a0significantly increase favorable outcomes compared with the standard of care. [23] [24]", "contents": "Nimodipine -- Indications. One Phase\u00a0III randomized trial compared the efficacy and safety\u00a0of\u00a0single intraventricular administration\u00a0nimodipine microparticles to the standard oral nimodipine\u00a0in patients with SAH.\u00a0The trial concluded that sustained release nimodipine administered via external ventricular drain did not\u00a0significantly increase favorable outcomes compared with the standard of care. [23] [24]"}
{"id": "article-25891_20", "title": "Nimodipine -- Indications", "content": "A recent\u00a0innovative\u00a0formulation has connected nimodipine with pH-sensitive chitosan nanoparticles. The objective of using\u00a0this technique\u00a0is to maintain systemic administration of nimodipine but restrict the release of the drug to tissues\u00a0in the ischemic penumbra with a lower pH. [25]", "contents": "Nimodipine -- Indications. A recent\u00a0innovative\u00a0formulation has connected nimodipine with pH-sensitive chitosan nanoparticles. The objective of using\u00a0this technique\u00a0is to maintain systemic administration of nimodipine but restrict the release of the drug to tissues\u00a0in the ischemic penumbra with a lower pH. [25]"}
{"id": "article-25891_21", "title": "Nimodipine -- Mechanism of Action", "content": "During the depolarization of smooth muscle cells of blood vessels, there is an influx of calcium ions. The primary function of nimodipine is to block voltage-gated L-type calcium channels and keep them in their inactive conformation, preventing vasoconstriction. Nimodipine\u00a0preferentially acts on cerebral blood vessels because it is lipophilic and can cross the blood-brain barrier. [26] Proposed mechanisms\u00a0leading to a beneficial effect include decreased angiographic vasospasm, increased fibrinolytic activity, and enhanced neuroprotection. [25]", "contents": "Nimodipine -- Mechanism of Action. During the depolarization of smooth muscle cells of blood vessels, there is an influx of calcium ions. The primary function of nimodipine is to block voltage-gated L-type calcium channels and keep them in their inactive conformation, preventing vasoconstriction. Nimodipine\u00a0preferentially acts on cerebral blood vessels because it is lipophilic and can cross the blood-brain barrier. [26] Proposed mechanisms\u00a0leading to a beneficial effect include decreased angiographic vasospasm, increased fibrinolytic activity, and enhanced neuroprotection. [25]"}
{"id": "article-25891_22", "title": "Nimodipine -- Mechanism of Action -- Pharmacokinetics", "content": "Absorption: Nimodipine is rapidly absorbed after oral administration, and peak concentration is achieved within 1.5 hours. Due to an elevated first-pass metabolism, the bioavailability of nimodipine is approximately 13% after oral administration.\u00a0Taking nimodipine with\u00a0meals results in a decreased peak plasma concentration and lower bioavailability\u00a0compared to fasting.", "contents": "Nimodipine -- Mechanism of Action -- Pharmacokinetics. Absorption: Nimodipine is rapidly absorbed after oral administration, and peak concentration is achieved within 1.5 hours. Due to an elevated first-pass metabolism, the bioavailability of nimodipine is approximately 13% after oral administration.\u00a0Taking nimodipine with\u00a0meals results in a decreased peak plasma concentration and lower bioavailability\u00a0compared to fasting."}
{"id": "article-25891_23", "title": "Nimodipine -- Mechanism of Action -- Pharmacokinetics", "content": "Distribution: The volume\u00a0of distribution (Vd) of nimodipine varies from 0.94\u00a0L/kg to 2.46\u00a0L/kg.\u00a0Nimodipine is\u00a0approximately 95% bound to plasma proteins, primarily to \u03b1-acid glycoprotein. Accordingly, the concentration of \u03b1-acid glycoprotein can influence the distribution of nimodipine. Metabolism: Nimodipine is metabolized by\u00a0CYP3A4 and CYP3A5. Multiple inactive or less active metabolites have been identified.", "contents": "Nimodipine -- Mechanism of Action -- Pharmacokinetics. Distribution: The volume\u00a0of distribution (Vd) of nimodipine varies from 0.94\u00a0L/kg to 2.46\u00a0L/kg.\u00a0Nimodipine is\u00a0approximately 95% bound to plasma proteins, primarily to \u03b1-acid glycoprotein. Accordingly, the concentration of \u03b1-acid glycoprotein can influence the distribution of nimodipine. Metabolism: Nimodipine is metabolized by\u00a0CYP3A4 and CYP3A5. Multiple inactive or less active metabolites have been identified."}
{"id": "article-25891_24", "title": "Nimodipine -- Mechanism of Action -- Pharmacokinetics", "content": "Elimination: The terminal elimination half-life of nimodipine is approximately 8 to 9 hours, but initial elimination is rapid (equivalent to a half-life of 1 to 2 hours); frequent (every 4 hours) dosing is necessary. Nimodipine is excreted primarily via the kidney, and less than 1% of the parent drug is recovered unchanged in the urine. Pharmacokinetic studies have documented the variability of nimodipine concentrations in patients with subarachnoid hemorrhage. [27]", "contents": "Nimodipine -- Mechanism of Action -- Pharmacokinetics. Elimination: The terminal elimination half-life of nimodipine is approximately 8 to 9 hours, but initial elimination is rapid (equivalent to a half-life of 1 to 2 hours); frequent (every 4 hours) dosing is necessary. Nimodipine is excreted primarily via the kidney, and less than 1% of the parent drug is recovered unchanged in the urine. Pharmacokinetic studies have documented the variability of nimodipine concentrations in patients with subarachnoid hemorrhage. [27]"}
{"id": "article-25891_25", "title": "Nimodipine -- Administration -- Available Dosage Forms", "content": "Nimodipine is available as oral tablets, oral solutions, and intravenous infusion solutions. However, the FDA has not approved the intravenous infusion solution, and this formulation is unavailable in the U.S. Nimodipine is available as a 30 mg oral capsule and an oral solution (6 mg/mL). The Neurocritical Care Society guidelines suggest that all patients with aneurysmal subarachnoid hemorrhage should receive oral nimodipine 60 mg every\u00a04 hours for 21 days\u00a0after an SAH occurs. [28]", "contents": "Nimodipine -- Administration -- Available Dosage Forms. Nimodipine is available as oral tablets, oral solutions, and intravenous infusion solutions. However, the FDA has not approved the intravenous infusion solution, and this formulation is unavailable in the U.S. Nimodipine is available as a 30 mg oral capsule and an oral solution (6 mg/mL). The Neurocritical Care Society guidelines suggest that all patients with aneurysmal subarachnoid hemorrhage should receive oral nimodipine 60 mg every\u00a04 hours for 21 days\u00a0after an SAH occurs. [28]"}
{"id": "article-25891_26", "title": "Nimodipine -- Administration -- Oral Administration", "content": "Nimodipine is available as liquid-filled oral capsules (30 mg) and oral solution (6 mg/mL and 30 mg/10 mL strength [unit-dose prefilled syringe and 8 oz container]). This drug must be administered at least 1 hour before or 2 hours after meals. Nimodipine should be administered\u00a0as early as possible but must\u00a0be administered within 96 hours of\u00a0a diagnosis of subarachnoid hemorrhage.\u00a0The recommended dose for adults is 60 mg (as 2 30 mg capsules) every 4 hours for 21 consecutive days. If the patient is not conscious enough to swallow the nimodipine capsule, the contents\u00a0can be\u00a0extracted into a syringe,\u00a0fed through a nasogastric tube, and washed down with 30 mL of normal saline (0.9%).", "contents": "Nimodipine -- Administration -- Oral Administration. Nimodipine is available as liquid-filled oral capsules (30 mg) and oral solution (6 mg/mL and 30 mg/10 mL strength [unit-dose prefilled syringe and 8 oz container]). This drug must be administered at least 1 hour before or 2 hours after meals. Nimodipine should be administered\u00a0as early as possible but must\u00a0be administered within 96 hours of\u00a0a diagnosis of subarachnoid hemorrhage.\u00a0The recommended dose for adults is 60 mg (as 2 30 mg capsules) every 4 hours for 21 consecutive days. If the patient is not conscious enough to swallow the nimodipine capsule, the contents\u00a0can be\u00a0extracted into a syringe,\u00a0fed through a nasogastric tube, and washed down with 30 mL of normal saline (0.9%)."}
{"id": "article-25891_27", "title": "Nimodipine -- Administration -- Intravenous Administration", "content": "Parental administration is strongly discouraged (see USFDA\u00a0boxed warning). The following parenteral techniques are described for educational purposes only. Nimodipine\u00a0can be given intravenously via a central venous catheter at a starting dose of 1 mg/h (15 \u03bcg/kg/h, equivalent to 5 mL/h) for the first 2 hours.\u00a0If the patient tolerates the drug well\u00a0without hypotension, the dose can\u00a0increase\u00a0to 2 mg/h (30 \u03bcg/kg/h, equivalent to 10 mL/h) after the first 2 hours. If the patient has hypotension or a body weight of less than 70 kg, nimodipine should\u00a0be started at 0.5 mg/h (2.5 mL of solution per hour) or less, if necessary.", "contents": "Nimodipine -- Administration -- Intravenous Administration. Parental administration is strongly discouraged (see USFDA\u00a0boxed warning). The following parenteral techniques are described for educational purposes only. Nimodipine\u00a0can be given intravenously via a central venous catheter at a starting dose of 1 mg/h (15 \u03bcg/kg/h, equivalent to 5 mL/h) for the first 2 hours.\u00a0If the patient tolerates the drug well\u00a0without hypotension, the dose can\u00a0increase\u00a0to 2 mg/h (30 \u03bcg/kg/h, equivalent to 10 mL/h) after the first 2 hours. If the patient has hypotension or a body weight of less than 70 kg, nimodipine should\u00a0be started at 0.5 mg/h (2.5 mL of solution per hour) or less, if necessary."}
{"id": "article-25891_28", "title": "Nimodipine -- Administration -- Intraventricular Administration", "content": "The outcome, dosage, and duration of intraventricular\u00a0nimodipine administration\u00a0were assessed in the NEWTON trial. The results of this trial indicated no significant\u00a0benefit for\u00a0intraventricular nimodipine compared with the standard of care. [23] [29]", "contents": "Nimodipine -- Administration -- Intraventricular Administration. The outcome, dosage, and duration of intraventricular\u00a0nimodipine administration\u00a0were assessed in the NEWTON trial. The results of this trial indicated no significant\u00a0benefit for\u00a0intraventricular nimodipine compared with the standard of care. [23] [29]"}
{"id": "article-25891_29", "title": "Nimodipine -- Administration -- Aneurysmal Subarachnoid Hemorrhage Treatment\u00a0Duration", "content": "Intravenous administration should be started as soon as possible after the onset of clinical vasospasm and should continue for a minimum of 5 days and a maximum of 14 days. If the condition\u00a0requires surgical intervention, nimodipine should\u00a0be administered at a steady\u00a0dose for at least 5 days. Intravenous nimodipine administration can begin\u00a0with or without pre-treatment with nimodipine tablets. However, if\u00a0nimodipine is administered intravenously following oral administration, the total duration of treatment should not exceed 21 days. Nimodipine should not be\u00a0administered intravenously\u00a0for more than 14 days. Patients should not\u00a0be administered intravenous and oral nimodipine concomitantly. During a surgical procedure, a 20 mL diluted solution of nimodipine (1 ml of nimodipine concentrated intravenous infusion solution and 19 mL of Ringer solution) warmed up to blood temperature may be\u00a0administered\u00a0intracisternally. This diluted solution must be used immediately after preparation.", "contents": "Nimodipine -- Administration -- Aneurysmal Subarachnoid Hemorrhage Treatment\u00a0Duration. Intravenous administration should be started as soon as possible after the onset of clinical vasospasm and should continue for a minimum of 5 days and a maximum of 14 days. If the condition\u00a0requires surgical intervention, nimodipine should\u00a0be administered at a steady\u00a0dose for at least 5 days. Intravenous nimodipine administration can begin\u00a0with or without pre-treatment with nimodipine tablets. However, if\u00a0nimodipine is administered intravenously following oral administration, the total duration of treatment should not exceed 21 days. Nimodipine should not be\u00a0administered intravenously\u00a0for more than 14 days. Patients should not\u00a0be administered intravenous and oral nimodipine concomitantly. During a surgical procedure, a 20 mL diluted solution of nimodipine (1 ml of nimodipine concentrated intravenous infusion solution and 19 mL of Ringer solution) warmed up to blood temperature may be\u00a0administered\u00a0intracisternally. This diluted solution must be used immediately after preparation."}
{"id": "article-25891_30", "title": "Nimodipine -- Administration", "content": "Specific Patient Population [28]", "contents": "Nimodipine -- Administration. Specific Patient Population [28]"}
{"id": "article-25891_31", "title": "Nimodipine -- Administration", "content": "Hepatic impairment: Bioavailability increases in patients with cirrhosis, making it necessary to reduce the dose in patients with this condition. The recommended dosage for patients with cirrhosis is 30 mg every 4 hours. Renal impairment: No information is available\u00a0on the manufacturer's label concerning\u00a0nimodipine dosing for patients with impaired renal function. Pregnancy considerations: Nimodipine\u00a0is a former U.S. FDA pregnancy category C medicine, and alternative agents are preferred.", "contents": "Nimodipine -- Administration. Hepatic impairment: Bioavailability increases in patients with cirrhosis, making it necessary to reduce the dose in patients with this condition. The recommended dosage for patients with cirrhosis is 30 mg every 4 hours. Renal impairment: No information is available\u00a0on the manufacturer's label concerning\u00a0nimodipine dosing for patients with impaired renal function. Pregnancy considerations: Nimodipine\u00a0is a former U.S. FDA pregnancy category C medicine, and alternative agents are preferred."}
{"id": "article-25891_32", "title": "Nimodipine -- Administration", "content": "Breastfeeding considerations: Based on the available data, nimodipine is\u00a0present in human milk; relative infant exposure is less and is not expected to cause adverse effects in breastfed infants. However, the decision to breastfeed during an episode of SAH merits a risk-benefit evaluation. [30]", "contents": "Nimodipine -- Administration. Breastfeeding considerations: Based on the available data, nimodipine is\u00a0present in human milk; relative infant exposure is less and is not expected to cause adverse effects in breastfed infants. However, the decision to breastfeed during an episode of SAH merits a risk-benefit evaluation. [30]"}
{"id": "article-25891_33", "title": "Nimodipine -- Administration", "content": "Pediatric patients: Nimodipine\u00a0is not FDA-approved for pediatric patients. Research indicates that administering oral nimodipine to children following subarachnoid hemorrhage does not eliminate vasospasm, infarction, or rebleeding. Nimodipine is also associated with significant hypotension. Further investigation, including dose titration, is\u00a0necessary\u00a0before administration to pediatric patients can be advised. [31]", "contents": "Nimodipine -- Administration. Pediatric patients: Nimodipine\u00a0is not FDA-approved for pediatric patients. Research indicates that administering oral nimodipine to children following subarachnoid hemorrhage does not eliminate vasospasm, infarction, or rebleeding. Nimodipine is also associated with significant hypotension. Further investigation, including dose titration, is\u00a0necessary\u00a0before administration to pediatric patients can be advised. [31]"}
{"id": "article-25891_34", "title": "Nimodipine -- Administration", "content": "Older patients: In older patients, clinicians should be cautious when dosing nimodipine\u00a0for patients with\u00a0reduced cardiac, hepatic,\u00a0or renal function. One case report\u00a0suggests that adverse effects like hypotension and AV block from nimodipine\u00a0can be more pronounced in older patients who\u00a0have\u00a0a\u00a0\"poor metabolizer\" CYP3A5 genotype. [32]", "contents": "Nimodipine -- Administration. Older patients: In older patients, clinicians should be cautious when dosing nimodipine\u00a0for patients with\u00a0reduced cardiac, hepatic,\u00a0or renal function. One case report\u00a0suggests that adverse effects like hypotension and AV block from nimodipine\u00a0can be more pronounced in older patients who\u00a0have\u00a0a\u00a0\"poor metabolizer\" CYP3A5 genotype. [32]"}
{"id": "article-25891_35", "title": "Nimodipine -- Adverse Effects", "content": "Nimodipine is usually well-tolerated orally, but its use correlates with some side effects related to\u00a0its use as a vasodilator. The\u00a0most common adverse effects of this medication include headache, vertigo, flushing, nausea, diarrhea, pedal edema, rash,\u00a0and palpitations.", "contents": "Nimodipine -- Adverse Effects. Nimodipine is usually well-tolerated orally, but its use correlates with some side effects related to\u00a0its use as a vasodilator. The\u00a0most common adverse effects of this medication include headache, vertigo, flushing, nausea, diarrhea, pedal edema, rash,\u00a0and palpitations."}
{"id": "article-25891_36", "title": "Nimodipine -- Adverse Effects", "content": "Acute colonic pseudo-obstruction (Ogilvie syndrome) has been\u00a0documented\u00a0in patients administered oral nimodipine. [33] Internal carotid and middle cerebral artery narrowing\u00a0leading to cerebral infarction have been reported\u00a05 months after\u00a0intraventricular administration\u00a0of sustained-release nimodipine. [29]", "contents": "Nimodipine -- Adverse Effects. Acute colonic pseudo-obstruction (Ogilvie syndrome) has been\u00a0documented\u00a0in patients administered oral nimodipine. [33] Internal carotid and middle cerebral artery narrowing\u00a0leading to cerebral infarction have been reported\u00a05 months after\u00a0intraventricular administration\u00a0of sustained-release nimodipine. [29]"}
{"id": "article-25891_37", "title": "Nimodipine -- Adverse Effects -- Drug-Drug Interactions", "content": "Nimodipine is\u00a0metabolized by the cytochrome P450 3A4 system. Drugs that inhibit this enzyme can\u00a0cause\u00a0elevated plasma concentrations of nimodipine.\u00a0These drugs include macrolide antibiotics (eg, erythromycin, clarithromycin, and telithromycin), protease inhibitors (eg, ritonavir, indinavir, nelfinavir, and saquinavir), \"-azole\" antimycotics (eg, ketoconazole, voriconazole, itraconazole), antidepressants (eg, nefazodone, fluoxetine), quinupristin/dalfopristin, cimetidine, and valproic acid. Grapefruit juice also inhibits this cytochrome system and should be avoided\u00a0by any patient\u00a0taking nimodipine. [32]", "contents": "Nimodipine -- Adverse Effects -- Drug-Drug Interactions. Nimodipine is\u00a0metabolized by the cytochrome P450 3A4 system. Drugs that inhibit this enzyme can\u00a0cause\u00a0elevated plasma concentrations of nimodipine.\u00a0These drugs include macrolide antibiotics (eg, erythromycin, clarithromycin, and telithromycin), protease inhibitors (eg, ritonavir, indinavir, nelfinavir, and saquinavir), \"-azole\" antimycotics (eg, ketoconazole, voriconazole, itraconazole), antidepressants (eg, nefazodone, fluoxetine), quinupristin/dalfopristin, cimetidine, and valproic acid. Grapefruit juice also inhibits this cytochrome system and should be avoided\u00a0by any patient\u00a0taking nimodipine. [32]"}
{"id": "article-25891_38", "title": "Nimodipine -- Adverse Effects -- Drug-Drug Interactions", "content": "Medications including\u00a0carbamazepine, phenobarbital (phenobarbitone), and phenytoin are CYP3A4 inducers. Concomitant administration of any of these medications enhances nimodipine's metabolism. This process\u00a0reduces nimodipine's serum concentration and increases the likelihood of treatment failure. [34]", "contents": "Nimodipine -- Adverse Effects -- Drug-Drug Interactions. Medications including\u00a0carbamazepine, phenobarbital (phenobarbitone), and phenytoin are CYP3A4 inducers. Concomitant administration of any of these medications enhances nimodipine's metabolism. This process\u00a0reduces nimodipine's serum concentration and increases the likelihood of treatment failure. [34]"}
{"id": "article-25891_39", "title": "Nimodipine -- Contraindications", "content": "The following are contraindications to nimodipine administration: A history of hypersensitivity reaction to nimodipine is an absolute contraindication. Liver failure and hypotension are relative contraindications for administering nimodipine. Concomitant administration with potent CYP3A4 inhibitors is also a relative contraindication. [34] Nimodipine is not entirely safe\u00a0for pregnancy (Category C under the former FDA system), and patients who are pregnant should only use it if a strong benefit-risk ratio has been determined. Breastfeeding is contraindicated while taking the drug due to the chance of harmful effects on the baby. Current research has not yet fully established safety for pediatric patients. [35] [30]", "contents": "Nimodipine -- Contraindications. The following are contraindications to nimodipine administration: A history of hypersensitivity reaction to nimodipine is an absolute contraindication. Liver failure and hypotension are relative contraindications for administering nimodipine. Concomitant administration with potent CYP3A4 inhibitors is also a relative contraindication. [34] Nimodipine is not entirely safe\u00a0for pregnancy (Category C under the former FDA system), and patients who are pregnant should only use it if a strong benefit-risk ratio has been determined. Breastfeeding is contraindicated while taking the drug due to the chance of harmful effects on the baby. Current research has not yet fully established safety for pediatric patients. [35] [30]"}
{"id": "article-25891_40", "title": "Nimodipine -- Contraindications -- USFDA\u00a0Boxed Warning", "content": "Do not administer nimodipine by parenteral routes. Serious, life-threatening adverse events, including death, cardiac arrest, hypotension, cardiovascular collapse, and bradycardia, have been reported when the drug\u00a0is injected parenterally.\u00a0The IV formulation of nimodipine is currently available in Europe but is not FDA-approved, so it is not available in the U.S. [25]", "contents": "Nimodipine -- Contraindications -- USFDA\u00a0Boxed Warning. Do not administer nimodipine by parenteral routes. Serious, life-threatening adverse events, including death, cardiac arrest, hypotension, cardiovascular collapse, and bradycardia, have been reported when the drug\u00a0is injected parenterally.\u00a0The IV formulation of nimodipine is currently available in Europe but is not FDA-approved, so it is not available in the U.S. [25]"}
{"id": "article-25891_41", "title": "Nimodipine -- Monitoring", "content": "Blood pressure monitoring is necessary for patients\u00a0administered nimodipine as it can cause hypotension. The risk of hypotension is\u00a0elevated in the following scenarios: [36]", "contents": "Nimodipine -- Monitoring. Blood pressure monitoring is necessary for patients\u00a0administered nimodipine as it can cause hypotension. The risk of hypotension is\u00a0elevated in the following scenarios: [36]"}
{"id": "article-25891_42", "title": "Nimodipine -- Monitoring", "content": "The plasma concentration of nimodipine\u00a0is elevated\u00a0by medications that moderately or weakly inhibit CYP3A4. Therefore, the patient's blood pressure\u00a0must be closely monitored if nimodipine is\u00a0administered concomitantly with\u00a0CYP3A4 inhibitors; reducing the nimodipine dose may be necessary.", "contents": "Nimodipine -- Monitoring. The plasma concentration of nimodipine\u00a0is elevated\u00a0by medications that moderately or weakly inhibit CYP3A4. Therefore, the patient's blood pressure\u00a0must be closely monitored if nimodipine is\u00a0administered concomitantly with\u00a0CYP3A4 inhibitors; reducing the nimodipine dose may be necessary."}
{"id": "article-25891_43", "title": "Nimodipine -- Monitoring", "content": "Nimodipine may\u00a0augment the blood pressure reduction\u00a0of concomitantly administered antihypertensives (eg, diuretics, \u03b2-blockers, ACE inhibitors, calcium antagonists, \u03b1-blockers, PDE5 inhibitors, \u03b1-methyldopa). Reducing the nimodipine dosage to prevent hypotension may be required.", "contents": "Nimodipine -- Monitoring. Nimodipine may\u00a0augment the blood pressure reduction\u00a0of concomitantly administered antihypertensives (eg, diuretics, \u03b2-blockers, ACE inhibitors, calcium antagonists, \u03b1-blockers, PDE5 inhibitors, \u03b1-methyldopa). Reducing the nimodipine dosage to prevent hypotension may be required."}
{"id": "article-25891_44", "title": "Nimodipine -- Monitoring", "content": "Patients with SAH should be monitored for hyponatremia, seizures, and vasospasm, especially during the 4 to 14-day \"vasospasm window.\" [37]", "contents": "Nimodipine -- Monitoring. Patients with SAH should be monitored for hyponatremia, seizures, and vasospasm, especially during the 4 to 14-day \"vasospasm window.\" [37]"}
{"id": "article-25891_45", "title": "Nimodipine -- Monitoring", "content": "Patients prescribed nimodipine are at risk for\u00a0elevated intracranial pressure and rebleeding. [38]", "contents": "Nimodipine -- Monitoring. Patients prescribed nimodipine are at risk for\u00a0elevated intracranial pressure and rebleeding. [38]"}
{"id": "article-25891_46", "title": "Nimodipine -- Monitoring", "content": "Patients with\u00a0SAH\u00a0must be monitored\u00a0with\u00a0comprehensive neurological examinations and grading scales (eg, Fisher grading scale). [39]", "contents": "Nimodipine -- Monitoring. Patients with\u00a0SAH\u00a0must be monitored\u00a0with\u00a0comprehensive neurological examinations and grading scales (eg, Fisher grading scale). [39]"}
{"id": "article-25891_47", "title": "Nimodipine -- Monitoring", "content": "Patients'\u00a0global disability and recovery should be monitored using the Glasgow Outcome Scale-Extended (GOSE). [40]", "contents": "Nimodipine -- Monitoring. Patients'\u00a0global disability and recovery should be monitored using the Glasgow Outcome Scale-Extended (GOSE). [40]"}
{"id": "article-25891_48", "title": "Nimodipine -- Toxicity -- Signs and Symptoms of Overdose", "content": "Acute\u00a0toxicity due to overdose can cause significant hypotension, cardiac arrhythmia, nausea, and vomiting. Refractory, nimodipine-induced vasoplegia\u00a0may occur.", "contents": "Nimodipine -- Toxicity -- Signs and Symptoms of Overdose. Acute\u00a0toxicity due to overdose can cause significant hypotension, cardiac arrhythmia, nausea, and vomiting. Refractory, nimodipine-induced vasoplegia\u00a0may occur."}
{"id": "article-25891_49", "title": "Nimodipine -- Toxicity -- Management of Overdose", "content": "No specific antidote is available. Overdoses are managed initially by discontinuing nimodipine and treating\u00a0symptoms. Gastric lavage\u00a0may be considered\u00a0if the toxicity is due to oral intake, and charcoal can\u00a0be administered in emergencies. Hypotension is managed with inotropes, and arrhythmias are managed by cardiologists and emergency department staff. Since nimodipine is highly protein-bound, dialysis is unlikely to be beneficial. [41] [42]  Recent case reports suggest hydroxocobalamin as a potential rescue therapy for nimodipine-induced refractory vasoplegia. [43]", "contents": "Nimodipine -- Toxicity -- Management of Overdose. No specific antidote is available. Overdoses are managed initially by discontinuing nimodipine and treating\u00a0symptoms. Gastric lavage\u00a0may be considered\u00a0if the toxicity is due to oral intake, and charcoal can\u00a0be administered in emergencies. Hypotension is managed with inotropes, and arrhythmias are managed by cardiologists and emergency department staff. Since nimodipine is highly protein-bound, dialysis is unlikely to be beneficial. [41] [42]  Recent case reports suggest hydroxocobalamin as a potential rescue therapy for nimodipine-induced refractory vasoplegia. [43]"}
{"id": "article-25891_50", "title": "Nimodipine -- Enhancing Healthcare Team Outcomes", "content": "Management\u00a0of aneurysmal subarachnoid hemorrhage with nimodipine is best carried out by\u00a0an interprofessional healthcare team. A cardiologist or internal medicine specialist frequently initiates this treatment. Nurses administer and monitor nimodipine treatment in the intensive care unit (ICU) and the neurosurgical floor.\u00a0Neuro-intensivists and neurosurgeons play a crucial role in\u00a0managing complex SAH cases. Before initiating nimodipine therapy, a pharmacist should be consulted on dosing and drug interactions. Interprofessional coordination of effort permits the healthcare team to obtain optimal outcomes with minimal adverse events. One study has\u00a0demonstrated that early and aggressive care of SAH leads to a significant\u00a0improvement in survival and favorable outcomes. [44]", "contents": "Nimodipine -- Enhancing Healthcare Team Outcomes. Management\u00a0of aneurysmal subarachnoid hemorrhage with nimodipine is best carried out by\u00a0an interprofessional healthcare team. A cardiologist or internal medicine specialist frequently initiates this treatment. Nurses administer and monitor nimodipine treatment in the intensive care unit (ICU) and the neurosurgical floor.\u00a0Neuro-intensivists and neurosurgeons play a crucial role in\u00a0managing complex SAH cases. Before initiating nimodipine therapy, a pharmacist should be consulted on dosing and drug interactions. Interprofessional coordination of effort permits the healthcare team to obtain optimal outcomes with minimal adverse events. One study has\u00a0demonstrated that early and aggressive care of SAH leads to a significant\u00a0improvement in survival and favorable outcomes. [44]"}
{"id": "article-25891_51", "title": "Nimodipine -- Enhancing Healthcare Team Outcomes", "content": "When administering nimodipine,\u00a0providers must be aware\u00a0of\u00a0hypotension as an adverse effect. After administration, careful blood pressure monitoring is necessary, especially in patients concomitantly receiving CYP3A4 inhibitors and antihypertensives. Administration of nimodipine is possible by pushing the tablet contents through\u00a0a nasogastric tube. In these cases, oral nimodipine should be labeled\u00a0and kept separate to avoid its administration intravenously.\u00a0An interprofessional team approach and open communication between clinicians (MDs, DOs, NPs, PAs), pharmacists, nurses, and specialists are necessary to\u00a0optimize patient outcomes with\u00a0nimodipine\u00a0therapy.", "contents": "Nimodipine -- Enhancing Healthcare Team Outcomes. When administering nimodipine,\u00a0providers must be aware\u00a0of\u00a0hypotension as an adverse effect. After administration, careful blood pressure monitoring is necessary, especially in patients concomitantly receiving CYP3A4 inhibitors and antihypertensives. Administration of nimodipine is possible by pushing the tablet contents through\u00a0a nasogastric tube. In these cases, oral nimodipine should be labeled\u00a0and kept separate to avoid its administration intravenously.\u00a0An interprofessional team approach and open communication between clinicians (MDs, DOs, NPs, PAs), pharmacists, nurses, and specialists are necessary to\u00a0optimize patient outcomes with\u00a0nimodipine\u00a0therapy."}
{"id": "article-25891_52", "title": "Nimodipine -- Review Questions", "content": "Access free multiple choice questions on this topic. Comment on this article.", "contents": "Nimodipine -- Review Questions. Access free multiple choice questions on this topic. Comment on this article."}